fluorouracil.... 300 mg/sqm IV days 1 to 5.
adriamycin...... 40 mg/sqm IV day 1.
cisplatin....... 60 mg/sqm IV day 1 with hydration.
FREQUENCY....... Repeat cycle every 5 weeks.
Moertel CG. Rubin J. O'Connell MJ. Schutt AJ. Wieand HS. A
phase II study of combined 5-fluorouracil, doxorubicin, and
cisplatin in the treatment of advanced upper gastrointestinal
adenocarcinomas. Journal of Clinical Oncology. 4(7):1053-7,
In a phase II study of 67 patients with upper gastrointestinal
carcinomas and measurable disease without previous
chemotherapy, we have evaluated the combination of intensive
course 5-fluorouracil (5-FU) (300 mg/m2/d for five days)
doxorubicin (40 mg/m2 on day 1), and cisplatin (60 mg/m2 on
day 1). Courses were repeated every 5 weeks. Among 26 patients
with gastric carcinoma, a 50% regression rate was obtained
with a median survival for all patients of 9 months. Among 29
patients with pancreatic carcinoma, the regression rate was
21% and the median survival was 4 months. Regressions were
also observed in smaller numbers of patients with carcinomas
of the gallbladder and ampulla of Vater, as well as in
cholangiocellular carcinoma of the liver. Toxic reactions were
usually clinically tolerable and consisted primarily of
nausea, vomiting, stomatitis, diarrhea, leukopenia, and
alopecia. Phase III studies are in progress to place the value
of this experimental regimen into clinical perspective.